Updated on 15 March 2013
At Aseacyte, human and animal cells are isolated as cyro-preserved stock and cell populations are characterized with cell marker analysis. Stem cells are grown in culture dishes to mimic what is happening in a whole-body environment and can be used to test a whole range of materials in a predictive way, including the complex mixture of natural compounds that is often found in herbal preparations. Cell identity is confirmed by fluorescence-activated cell sorting, using multiple cell surface markers.
The company has developed expertise in working with human primary cells, which are prepared from human tissues that have been sourced with ethical permission. The firm also stringently complies with international regulations on the use of human tissues in preclinical research and development. AseaCyte has a bank of cells categorized into diseased and healthy models. The diseased model catalogues help in the study of different diseases. For instance, cells from fully-characterized primary cancer cells, each isolated from individual donors and supplied with a full patient history, are stored and supplied. Similarly, cells are classified for studying glioblastoma, colon cancer, lung cancer, respiratory diseases, chronic obstructive pulmonary diseases and metabolic diseases.
Healthy cells can be the catalyst in the study of toxicology in human body, such as hepatic primary stellate cells for liver diseases, renal cortex primary fibroblasts for kidney diseases and skeletal myoblasts for muscle. Healthy human cells from tissues play a critical role in absorption, distribution, metabolism and excretion of candidate pharmaceuticals, natural products, food components and nanoparticles.
Cells are typically supplied with a recommended protocol for cell recovery from the frozen state and with general information on cell performance in culture. AseaCyte's cell biology and cell culture technology are relevant to major human disease areas and could be a key contributor to pharmaceuticals, natural product therapeutics, nutraceuticals and nano-materials industries for predicting therapeutic bio-activity and bio-safety.
"The cells are supplied with quality control data confirming absence of HIV, HBV and HCV human viruses, and mycoplasma contamination through PCR-based methodology and ELISA, respectively," says Dr Teo Soo Hwang, founder member and CEO, AseaCyte.